Magnisense
Magnisense develops and markets a new generation of immunoassays for human andanimal diagnostics, food safety and environmental protection. These innovative immunoassays are based on magnetic particle markers, which deliver the accuracyoflaboratory testing with the ease of use of rapid test methods currently on the market.
Magnisense's MIAtek(TM) technology allows the detection and precise quantification of a biological target using superparamagnetic particles as markers. These particles, free of interference from environmental factors that affect other approaches, replace the widely used enzyme- or fluorescence-based markers. MIAtek(TM) was developed from research carried out by the Russian Academy of Sciences.
Magnisense is developing two application areas:
MIAstrip(TM): point of care testing with a single dose, producing objective,quantifiable and traceable results via a portable reader for cardiac, tetanus,microbial or viral infection markers among others.
MIAflo(TM): disposable cartridges for detection of bacterial contamination in food products, e.g. Listeria and Salmonella, or in water, e.g. Legionella,with a sensitivity that brings a significant reduction in testing time.
Founded in 2003, Magnisense has raised two rounds of financing for a total of EUR 5.5 million from Baring Vostok Capital Partners and private investors.
Neil Hunter, Andrew Lloyd & Associates, www.ala.com,e-mail: neil@ala.com Brighton Business Centre,95 Ditchling Road, Brighton BN 1 4ST, England.
